Clinical trialsCompany release

Dogwood completes Phase 2b enrolment for Halneuron in chemotherapy-induced neuropathic pain; data due November

🇺🇸 Dogwood Therapeutics, Inc. (DWTX) · Thu 05 Nov 2026

Dogwood Therapeutics has enrolled 239 patients in its Phase 2b CINP trial of Halneuron, expects top-line results in November, and raised $5 million from its largest shareholder.

Dogwood Therapeutics reported its third quarter 2026 results on 5 November, saying it has completed enrolment of 239 patients in the Phase 2b trial of Halneuron in chemotherapy-induced neuropathic pain (CINP). The company expects top-line data from the study in November.

A long-term extension study of Halneuron has also been fully enrolled, with 95 patients. The summary of the results does not give further detail on the design, dosing or endpoints of either study.

On financing, Dogwood closed a $5 million private placement with Sealbond Limited, which the company identifies as its largest shareholder. For the quarter, it reported a net loss of $4.9 million.

The source material available was limited to the company's headline announcement, so details such as cash position, operating expenses and the timing of any subsequent regulatory steps are not covered here.

What it means for your team

  • Top-line Phase 2b CINP data for Halneuron are expected in November, the next clear milestone for the programme.
  • The fully enrolled 95-patient extension study means longer-term safety and tolerability data may follow, which would be of interest to pharmacovigilance teams tracking the product.
  • CINP remains an area of unmet need; teams monitoring supportive-care and oncology pain markets should watch for the trial readout.
  • The $5 million placement from Sealbond Limited is a modest funding step for a clinical-stage company; further financing details were not provided.

Company's press release (SEC filing): Dogwood Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Dogwood Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →